Background SLE is an inflammatory condition associated with hyperactivation of the immune system, with mounting evidence that imbalances in the gut microbiota communities are common. These imbalances ...

Objective Both belimumab and telitacicept are recognised blockers for B lymphocyte activation, both of which have been approved as add-on therapies for SLE in China. The aim of this study is to ...

Results Of 495 patients included, between 21.0% and 52.1% had ≥1 record for each of the disease activity measures or laboratory values in the pre-index and post-index periods and were included in ...

Background Premature vascular disease is a major major clinical problem and the major cause of the shortened life expectancy observed among patients with SLE in modern societies. Both ischemic heart ...

Objectives This study aimed to investigate serum glutathione reductase (GR) levels in patients with SLE and to assess its association with disease activity.Methods The retrospective study collected ...

Background Belimumab and low dose IL2 (Ld-IL2) has been identified effective in the treatment of systemic lupus erythematosus (SLE). However, the application of combined therapy for SLE has not been ...

Objective To evaluate the clinical utility of the multianalyte assay panel (MAP), commercially known as AVISE Lupus test (Exagen Inc.), in patients suspected of SLE.Methods A systematic review of ...

Background and aims The many manifestations of Lupus can jeopardise aspects of daily living in those with the disease. The aim of this study was to synthesise findings of primary and secondary studies ...

Purpose to identify the presence of variants in gene related to monogenic lupus and their relationship with clinical manifestations in childhood-onset systemic lupus erythematosus (cSLE) or lupus-like ...

Background Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with a strong genetic component (Block, Winfield et al. 1975, Deapen, Escalante et al. 1992, Alarcon- Segovia, ...

The axiom in ASCVD science supports circulating monocytes as a cellular hallmark of atherosclerosis.2 A major subset (80–90%) of circulating monocytes are classical (CD14+CD16-) monocytes. While ...

Background Pre-clinical mouse models are invaluable tools to investigate the mechanisms driving systemic lupus erythematosus (SLE) and identify therapeutic targets to treat human disease. The BXSB.Yaa ...